AstraZeneca Completes $2.4B Deal To Buy Pharma Co. Fusion
Drugmaker AstraZeneca said on Wednesday that it has bought Fusion Pharmaceuticals Inc., a Canadian company that specializes in oncology, for $2.4 billion in cash to bolster its range of cancer treatments....To view the full article, register now.
Already a subscriber? Click here to view full article